SKYRIZI HEAD-2-HEAD
DATA VS 3 AGENTS
FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN ADULTS1
SKYRIZI VS COSENTYX®
(secukinumab)2*
SKYRIZI VS STELARA®
(ustekinumab)1,4†
SKYRIZI VS HUMIRA®
(adalimumab)5
DISCOVER HOW SKYRIZI
PERFORMED VS 3 AGENTS
Rectangle
In different biologic classes
*SOURCING: In this study, 46 patients outside of the US received non–
US-licensed secukinumab. Data regarding comparability between US and
non-US secukinumab are not publicly available.3
†ACTIVE COMPARATOR: The ustekinumab used as a biologic active
control in UltIMMa-1 and UltIMMa-2 was sourced from the European
Union. Comparability between non–US-approved ustekinumab and
US-approved ustekinumab has not been established.